Growing R&D Of New Peptides Is Fostering The Growth Of The Peptide-Based Cardiovascular Therapeutics Market
The increasing prevalence of the cardiovascular disease is fueling the growth of the peptide-based cardiovascular therapeutics market. According to the World Health Organization, 17.9 million people die each year from CVDs, an estimated 31% of all deaths worldwide. >75% of CVD deaths occur in low- and middle-income countries. 85% of all CVD deaths are due to heart attacks and strokes. Also, according to American Heart Association’s Heart Disease and Stroke Statistics 2018, around 92.1 million adults in the U.S. are suffering from some form of CVD or the after-effects of stroke. North America is expected to dominate the global peptide-based cardiovascular therapeutics market and this is accredited to the increasing healthcare expenditure in the region. For instance, according to the Centers for Medicare & Medicaid Services (CMS), health spending in the U.S. is projected to grow at an average rate of 5.5% per year for 2018-27 and to reach nearly US$ 6.0 trillion by 2027. Add...